Codexis (CDXS) Stock: Buy, Sell, or Hold?
CDXS - Codexis, Inc.
$1.28
-0.03 (-2.29%)
▼
5d:
+3.23%
30d:
-6.57%
90d:
-17.42%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 05, 2026
12d
Get Alerted When CDXS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: CDXS shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: CDXS shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: CDXS is currently trading at $1.28, which is considered oversold relative to its 30-day fair value range of $1.30 to $1.41. From a valuation perspective, the stock is trading at a discount (Forward PE: -4.1) compared to its historical average (16.6). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CDXS is in a strong downtrend. Immediate support is located at $1.21, while resistance sits at $1.43.
Market Sentiment: CDXS scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.14 (+368.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CDXS is in a strong downtrend. Immediate support is located at $1.21, while resistance sits at $1.43.
Market Sentiment: CDXS scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.14 (+368.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.30 -
$1.41
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 368.9% below Wall St target ($6.14)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 52/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.30 -
$1.41
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.21
Resistance Level
$1.43
Current Trend
Strong Downtrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.09
Wall Street Target
$6.14
(+368.9%)
Revenue Growth (YoY)
-2.7%
Profit Margin
-39.6%
PE vs Historical
-4.1 vs 16.6
CHEAP
Share & Embed Analysis
Last updated: October 23, 2026 1:04 PM ET
Data refreshes hourly during market hours. Next update: 2:04 PM
Data refreshes hourly during market hours. Next update: 2:04 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CDXS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RVMD
Revolution Medicines Inc |
STRONG BUY
24 analysts |
$258 | 61 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
21 analysts |
$95 | 50 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$72 | 48 HOLD |
|
JANX
Janux Therapeutics Inc |
STRONG BUY
18 analysts |
$36 | 43 HOLD |
|
OCUL
Ocular Therapeutix Inc |
STRONG BUY
12 analysts |
$26 | 61 BUY |
